Acute Heart Failure (AHF) Therapeutics: A Global Strategic Business Report
San Jose, California (PRWEB) July 09, 2012
Follow us on LinkedIn – Acute Heart Failure (AHF) is a fatal condition, in which the heart loses its ability to pump sufficient blood to the other parts of the body and can present itself as acute de novo or acute decompensation heart failure (ADHF). In case if left untreated, ADHF leads to disability or even death. Presently, acute heart failure represents the primary cause of hospitalization among patients above 65 years of age. Despite the increasing prevalence rates, treatments related to AHF continue to remain tepid, lacking any noteworthy major development over the past several years. Therefore, AHF market is characterized by the presence of high mortality and rehospitalization rates, outcome of which is huge in terms of rising patient population, bulging costs, and poor prognosis rates. Also, the market size for AHF therapeutics is modest, as diuretics and inotropic agents which constitute the major portion of the AHF treatment are the traditional medicines used for cardiovascular diseases and are generic and inexpensive by nature, thereby contributing less towards the overall market value of acute heart failure.
The treatment for AHF has not undergone any major change in the past few decades, with the treatments still being based on loop diuretics furosemide, peripheral vasodilators (nitrates), and inotropic agents. Various forms of treatments are given to patients diagnosed under various stages of clinical conditions. These treatments, despite providing solace for short term problems, have however proved to increase mortality rates over the long term. Also, despite certain new agents such as Natrecor (nesiritide) and Simdax (levosimendan) gaining approvals in the US and certain regions of Europe respectively, their impact towards the treatment of AHF has been negligible, thereby making AHF an area with high presence of unmet needs.
Furthermore, the number of pipeline drugs presently undergoing clinical trials is not particularly encouraging when compared to the targets under clinical development for other cardiovascular incidences. This is despite of the fact that certain drugs, such as Relaxin (Novartis), have managed to create a buzz in the market over the years. In the years to come, it is estimated that any drug which can showcase promising results in terms of improved efficacy, safety, and mortality can reap huge benefits. Also, growing ageing population, resulting in increased incidence levels coupled with the launch of promising drugs are all expected to strengthen the growth prospects in the marketplace.
As stated by the new market research report on Acute Heart Failure Therapeutics, the US continues to remain the largest and the fastest growing regional market. In the US, AHF represents a small portion of the overall heart failure market and over the years pharma companies have found AHF market to be less attractive, due to the presence of a lesser number of patient population. Therefore, over the past few decades, the treatment options for AHF have not witnessed any major breakthroughs. Also, AHF market in the US was marred by the controversy related to Natrecor, as after a decade after approval, the drug was found to be ineffective in reducing re-hospitalization rates as well as mortality rates in patients diagnosed with ADHF. However, the US FDA has acknowledged the presence of huge unmet needs in the AHF therapeutics scenario and some promising drugs such as Cenderitide and Relaxin have been accorded fast track designations.
Major players in the marketplace include Abbott Laboratories, Bayer AG, Cardiokine Inc., Cardioxyl Pharmaceuticals Inc., EKR Therapeutics Inc., Hospira Inc., Johnson & Johnson, Nile Therapeutics Inc., Novartis International AG, Orion Corp., Trevena Inc., Valeant Pharmaceuticals, among others.
The research report titled "Acute Heart Failure (AHF) Therapeutics: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of acute heart failure therapies, market trends, issues, therapeutic treatment for AHF, clinical trials, strategic corporate initiatives, and profiles of major companies worldwide, along with an insight into AHF causes, symptoms, and evaluation methods. The report provides annual sales estimates and projections for Acute Heart Failure (AHF) Therapeutics market for the years 2010 through 2018 for the following geographic markets - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World. Also, a six-year (2004-2009) historic analysis is provided for additional perspective.
For more details about this comprehensive market research report, please visit –
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/